EGFR and neoplasm: These EGFR TKIs have effectively replaced chemotherapy as the first line treatment [87], Unfortunately, EGFR is increasingly recognized as a biomarker of tumor resistance [84], since all patients with metastatic lung who initially benefit from EGFR-targeted therapies eventually developed resistance [88].